Introduction {#s01}
============

Chemotherapy is a major method for treating advanced malignant tumors in the digestive system ([@b1]-[@b3]). When drugs are administered intravenously, a small amount infiltrates the tumor tissue, while a large amount is delivered to the normal tissues of the body through the blood circulation, thus leading to adverse reactions ([@b4],[@b5]). One of the most important factors limiting the effectiveness of chemotherapy is the primary and secondary resistance of cancer cells ([@b6],[@b7]). Ultrasound sonoporation is a new method of local drug delivery which has been applied in medical research due to its noninvasiveness, local applicability, and proven safety as an ultrasonographic imaging technique ([@b8],[@b9]). This method restricts the release of the drugs to a focal ultrasound zone and enhances the effect of chemotherapy in sonoporated areas ([@b10],[@b11]). Microbubbles thus offer considerable promise as a means of improving the therapeutic efficiency of chemotherapy, as well as decreasing toxicity to healthy tissues ([@b12],[@b13]).

The mechanism by which sonoporation enhances the sensitivity of chemotherapy relies on a cavitation effect and a mechanical effect ([@b14]-[@b16]). The sonoporation effect occurs by means of the characteristics of microbubbles under different mechanical indexes (MIs) ([@b17]-[@b19]). Clinically applied microbubbles are 2−8 mm bubbles composed of sulfur hexafluoride gas encapsulated by phospholipid. The microbubbles are stable under a low MI, which is applied during imaging. Under a high MI, microbubbles injected into the blood circulation undergo a series of dynamic processes, such as oscillation, expansion and contraction, and release mechanical energy, such as shockwaves and microjets, at the moment of bubble cavitation ([@b20],[@b21]). As tumor neovascularization is incomplete, weak and highly permeable, mechanical energy can directly cause formation of transient pores thus increasing the permeability of the cell membrane, which is known as the sonoporation effect ([@b22]-[@b24]). The sonoporation effect has been demonstrated to significantly increase the penetration of chemotherapeutic drugs into tumor cells and increase the drug concentration ([@b25],[@b26]). In addition, more drug binding sites can be exposed to increase the sensitivity of the tumor to chemotherapy ([@b27]).

At present, research is mainly at the stage of animal experimentation ([@b28]-[@b30]). However, clinical studies on the use of ultrasound with microbubbles are few. Kotopoulis *et al*. took the lead in performing a clinical trial of ultrasound combined with microbubbles for enhancing the chemotherapeutic sensitivity of pancreatic cancer ([@b31]). As the current clinical studies were at the primary stage of research regarding ultrasound combined with microbubbles, this study mainly focused on the safety of this technique for enhancing the chemotherapeutic sensitivity of digestive malignancies to lay the foundation for further studies of effectiveness.

Materials and methods {#s02}
=====================

This study was registered in Clinicaltrials.gov (No. NCT02233205), and was approved by the Ethical Committee of Peking Unicersity Cancer Hospital. All the patients signed informed consent before they were enrolled in the study. The detailed schedule of this study is shown in *[Table 1](#Table1){ref-type="table"}*.

###### 

Detailed schedule of this study

  -------------------------------------------------------------------------------------------------------------------------------------------
  Items                                     Screening stage   Treatment period (cycle)   End   Observation stage   Follow-up period       
  ----------------------------------------- ----------------- -------------------------- ----- ------------------- ------------------ --- ---
  Signed informed consent                   X                                                                                             

  Histological or cytological examination   X                                                                                             

  Tumor evaluation (TNM)                    X                                                                                             X

  Inclusion and exclusion criteria          X                 X                                                                           

  Past medical history                      X                 X                                                                           

  ECOG scoring                              X                 X                          X     X                   X                  X   X

  Vital signs                               X                 X                          X     X                   X                  X   X

  Physical examination                      X                 X                          X     X                   X                  X   X

  Hematological examination                 X                 X                          X     X                   X                  X   X

  Biochemical analysis                      X                 X                          X     X                   X                  X   X

  Hematuria amylase\                        X                 X                          X     X                   X                  X   X
  (pancreatic tumors)                                                                                                                     

  Urine analysis                            X                 X                          X     X                   X                  X   X

  Electrocardiogram                         X                 X                          X     X                   X                  X   

  Image examination                         X                 Two or three cycles        X     X                                          

  Treatment                                                   X                          X     X                   X                      

  Collection of adverse reactions                             X                          X     X                   X                  X   X

  Evaluation of survival status                               X                          X     X                   X                  X   X
  -------------------------------------------------------------------------------------------------------------------------------------------

Study subjects {#s02.01}
--------------

The study group comprised patients with liver metastases from malignant tumors of the digestive system (gastric cancer, colon cancer, etc.) and patients with pancreatic cancer. They all had previously failed routine chemotherapy, volunteered to participate in the study and met the inclusion criteria. The inclusion criteria were as follows: 1) age between 18−75 years old; 2) male or female; 3) histological or cytological diagnosis of liver metastasis from a malignant tumor of the digestive system (gastric cancer, colon cancer, etc.) or from pancreatic cancer; 4) previous failure of routine chemotherapy; 5) measurable and evaluable tumor lesions on images \[using enhanced computed tomography (CT) or magnetic resonance imaging (MRI)\]; 6) physical status Eastern Cooperative Oncology Group (ECOG) score ≤2; and 7) expected survival of more than 12 weeks.

Eighteen study subjects were originally identified for inclusion. Fifteen patients were classified into five groups (groups A, B, C, D and E), and each group contained three patients. If serious adverse reactions occurred, another three patients were included. The first four groups were classified according to MI from low to high. Group E had the same MI as group D, but had double the treatment time of ultrasound combined with microbubbles. As patients after chemotherapy often had multiple adverse reactions and physical decline, the longer treatment time with ultrasound combined with microbubbles was clinically unrealistic, and three patients in the last group (group E) were excluded. Between October 2014 and June 2016, 12 patients met the enrollment criteria and completed the follow-up (*[Figure 1](#Figure1){ref-type="fig"}*).

![Flow chart for study enrollment.](cjcr-30-5-553-1){#Figure1}

Ultrasonographic machine and contrast agent {#s02.02}
-------------------------------------------

A LogiQ E9 ultrasonic diagnostic apparatus and C1-5 abdominal convex probe (GE Healthcare, Milwaukee, Wisconsin, USA) were used. Sonovue (Bracco, Milan, Italy) was used as microbubbles. Lyophilized SonoVue powder was dissolved in 5 mL of saline. Two milliliters of the suspension was injected into the antecubital vein via a 20-G cannula within 2−3 s, followed by a 5 mL saline flush.

Treatment methods {#s02.03}
-----------------

According to the patient's history and condition, appropriate chemotherapy regimens were determined by experienced physicians in the Department of Gastrointestinal Oncology. All the second-line chemotherapy regimens, dosages and cycles are shown in *[Table 2](#Table2){ref-type="table"}*. All chemotherapy regimens were administered intravenously.

With half an hour after intravenous chemotherapy, the patients came to the Department of Ultrasound to receive treatment of ultrasound combined with microbubbles. First, the tumor was located in the center of image by transcutaneous ultrasound through the abdominal wall. Then, contrast mode was entered. One milliliter contrast agent suspension was injected through a vein. The perfusion time for the microbubbles was set to 6 s. Then, contrast mode was exited. The breaking time for the microbubbles was set to 4 s. One milliliter of contrast agent suspension was injected every 4 min. The perfusion and breaking processes were repeated. A total of 5 mL of contrast agent suspension was injected. After the end of treatment, the patients returned to the ward when no obvious discomfort was observed.

Energy increasing principle {#s02.04}
---------------------------

The ultrasonic energy design used the traditional Modified Fibonacci dose increasing method. The primary MI of Group A was set at 0.4 according to experience of Kotopoulis *et al*. ([@b31]). The MIs of the other three groups were 0.6, 0.8 and 1.0, respectively. There were 3 patients in each group at first. If no serious adverse reactions occurred in the group, the experiment was performed on the next group. If 1/3 of patients (1 patient) in a group experienced serious adverse reactions, 3 patients were added to the group (for a total of 6 patients in the group). If the three additional patients had no serious complications, the next group of experiments was performed. If ≥1 patient among the three added patients or ≥2 patients among the total 6 patients had serious adverse reactions, the maximum energy tolerance level was determined to be reached. Once the maximum tolerance level was reached, the energy level was not increased. In addition, another 3 patients were included in a group to evaluate the energy level just below the maximum tolerance level. If one patient among those three patients had a serious adverse reaction, the main investigator decided whether to stop the study.

Clinical evaluation and follow-up {#s02.05}
---------------------------------

### Safety evaluation {#s02.05.01}

Safety evaluations included physical examinations, assessment of vital signs, physical status scoring, routine hematology and biochemical laboratory tests, assessment of hematuria and amylase levels, evaluation of electrocardiography (ECG) changes, etc. The safety assessment included observing and recording all adverse events, which were graded from 0−4 according to the Common Terminology Criteria for Adverse Events version 4.03 (CTCAE V4.03). Adverse events included pain, loss of appetite, fatigue, fever, nausea and vomiting, diarrhea, bloating, myelosuppression and neurotoxicity, etc.

### Efficacy evaluation {#s02.05.02}

The contrast-enhanced CT and MRI studies were used to assess the efficacy of ultrasound combined with microbubbles. The targeted tumors of each patient after treatment were evaluated according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteria: complete response (CR) was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduced along their short axis to \<10 mm. Partial response (PR) was defined as at least a 30% decrease in the sum of the diameters of the target lesions, using the baseline sum diameters as a reference. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of the target lesions, using the smallest sum on record as a reference. Stable disease (SD) was defined as neither sufficient reduction in size to be defined as PR nor a sufficient increase in size to be defined as PD, using the smallest sum diameters on record as a reference.

### Follow-up {#s02.05.03}

Eleven patients withdrew from the study due to tumor progression, and one patient voluntarily discontinued treatment. All patients were followed up until PD occurred. If serious complications occurred, the patients were followed up until remission of these adverse reactions.

Results {#s03}
=======

Clinical data of enrolled patients {#s03.01}
----------------------------------

The 12 enrolled patients were divided into four groups according to MI, and each group had 3 patients. There were 10 males and 2 females. The median age was 60 (range, 51−65) years old. Eleven patients had hepatic metastases, among which 5 had a pathological diagnosis, and 6 had a clinical diagnosis. All 11 patients had a pathological diagnosis of the primary lesions. One patient was pathologically diagnosed with pancreatic carcinoma. A total of 56 treatments with ultrasound combined with microbubbles were performed. The detailed clinical data of the patients are shown in*[Table 2](#Table2){ref-type="table"}*.

###### 

Clinical data of enrolled patients

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  Number   Sex      Age\     Location   Pathological type                   Primary location   Staging   Chemotherapy regimen   Mechanical index   Times
                    (year)                                                                                                                         
  -------- -------- -------- ---------- ----------------------------------- ------------------ --------- ---------------------- ------------------ -------
  A1       Male     51       Liver      Poorly differentiated\              Pancreas           T4N1M1    FOlFOXIRI^1^           0.4                9
                                        adenocarcinoma                                                                                             

  A2       Male     54       Liver      Moderately differentiated\          Colon              T4N1M1    FOLFIRI +\             0.4                3
                                        adenocarcinoma                                                   Cetuximab^2^                              

  A3       Male     55       Liver      Moderately differentiated\          Gallbladder        T4N1M1    Gemox^3^               0.4                2
                                        adenocarcinoma                                                                                             

  B1       Male     63       Liver      Moderately differentiated\          Colon              T4N1M1    FOLFIRI +\             0.6                6
                                        adenocarcinoma                                                   Cetuximab                                 

  B2       Male     61       Liver      Moderately differentiated\          Colon              T4N1M1    Irinotecan +\          0.6                3
                                        adenocarcinoma                                                   Cetuximab^4^                              

  B3       Female   64       Liver      Moderately differentiated\          Colon              T4N1M1    FOLFIRI +\             0.6                9
                                        adenocarcinoma                                                   Bevacizumab^5^                            

  C1       Male     62       Liver      Neuroendocrine\                     Colon              T4N1M1    Irinotecan^6^          0.8                2
                                        carcinoma                                                                                                  

  C2       Female   58       Pancreas   Mucous moderately differentiated\   Pancreas           T4N1M1    Gemcitabine +\         0.8                2
                                        adenocarcinoma                                                   S-1^7^                                    

  C3       Male     59       Liver      Moderately differentiated\          Colon              T3N1M1    FOLFIRI +\             0.8                6
                                        adenocarcinoma                                                   Bevacizumab                               

  D1       Male     65       Liver      Moderately differentiated\          Colon              T3N1M1    FOLFIRI + Cetuximab    1.0                6
                                        adenocarcinoma                                                                                             

  D2       Male     64       Liver      Moderately differentiated\          Colon              T4N1M1    XELOX^8^               1.0                2
                                        adenocarcinoma                                                                                             

  D3       Male     51       Liver      Moderately differentiated\          Colon              T4N1M1    FOLFOXIRI              1.0                6
                                        adenocarcinoma                                                                                             
  --------------------------------------------------------------------------------------------------------------------------------------------------------

Adverse reactions of enrolled patients {#s03.02}
--------------------------------------

According to the CTCAE V4.03, no serious adverse reactions occurred in all the patients included in the study. The pressure of the probe on the surface of the patients' skin did not increase local pain. The adverse reaction rate is shown in *[Table 3](#Table3){ref-type="table"}*. Of the adverse reactions recorded, level 2 bone marrow suppression occurred in one patient (2 times), and level 2 vomiting occurred in one patient (6 times). Other adverse events including loss of appetite, fatigue, fever, nausea and vomiting, diarrhea, bloating, myelosuppression and neurotoxicity were all level 1 adverse reactions. Among all the adverse reactions, the duration of bone marrow suppression lasted for less than two weeks and the duration of other adverse reactions lasted for less than one week. All the adverse reactions resolved with close observation or symptomatic treatment.

###### 

Adverse reactions rates of enrolled patients

  Adverse reactions         n (%)      
  ------------------------- ---------- -----------
  Loss of appetite                     
  　Grade 1                 5 (41.7)   22 (39.3)
  　Grade 2                 −          −
  Fatigue                              
  　Grade 1                 5 (41.7)   18 (32.1)
  　Grade 2                 −          −
  Fever                                
  　Grade 1                 2 (16.7)   3 (5.4)
  　Grade 2                 −          −
  Nausea                               
  　Grade 1                 7 (58.3)   31 (55.4)
  　Grade 2                 −          −
  Vomiting                             
  　Grade 1                 −          −
  　Grade 2                 1 (8.3)    6 (10.7)
  Bloating                             
  　Grade 1                 1 (8.3)    2 (3.6)
  　Grade 2                 −          −
  Diarrhea                             
  　Grade 1                 4 (33.3)   12 (21.4)
  　Grade 2                 1 (8.3)    1 (1.8)
  Constipation                         
  　Grade 1                 2 (16.7)   4 (7.1)
  　Grade 2                 −          −
  Bone marrow suppression              
  　Grade 1                 2 (16.7)   13 (23.2)
  　Grade 2                 1 (8.3)    2 (3.6)
  Neurotoxicity                        
  　Grade 1                 2 (16.7)   15 (26.8)
  　Grade 2                 −          −

Apart from fever, the other adverse reactions are common adverse reactions of second-line chemotherapy for malignant tumors of the digestive system. In this study, level 1 fever occurred in 2 patients (3 times), which might be related to treatment with the combination of ultrasound and microbubbles.

Adverse reactions of enrolled patients with different MIs {#s03.03}
---------------------------------------------------------

The adverse reactions associated with different MIs are shown in *[Table 4](#Table4){ref-type="table"}*. Among all the adverse reactions, fever, diarrhea, vomiting and bone marrow suppression resolved after symptomatic treatment. When the MI was 0.4, level 1 fever occurred in 2 patients (3 times), level 1 diarrhea occurred in 2 patients (6 times), and level 1 bone marrow suppression occurred in 2 patients (13 times). When the MI was 0.6, level 1 diarrhea occurred in 1 patient (1 time). When the MI was 0.8, level 2 bone marrow suppression occurred in 1 patient (2 times). When the MI was 1.0, level 2 vomiting occurred in 1 patient (6 times), level 1 diarrhea occurred in 1 patient (5 times), and level 2 diarrhea occurred in 1 patient (1 time). All the adverse reactions were grade 1 or 2. The severity of adverse reactions did not increase with increases in MI. Therefore, when the MI was no more than 1.0, treatment with ultrasound combining with microbubbles to enhance chemotherapeutic sensitivity was safe.

###### 

Adverse reactions rates of patients with different mechanical indexes

  Adverse reactions         Mechanical index                                     
  ------------------------- ------------------ ---- -- --- --- -- --- --- -- --- ---
  Loss of appetite                                                               
  　Grade 1                 1                  6       2   8      1   2      1   6
  　Grade 2                 −                  −       −   −      −   −      −   −
  Fatigue                                                                        
  　Grade 1                 −                  −       2   8      1   2      2   8
  　Grade 2                 −                  −       −   −      −   −      −   −
  Fever                                                                          
  　Grade 1                 2                  3       −   −      −   −      −   −
  　Grade 2                 −                  −       −   −      −   −      −   −
  Nausea                                                                         
  　Grade 1                 3                  14      1   3      2   8      1   6
  　Grade 2                 −                  −       −   −      −   −      −   −
  Vomiting                                                                       
  　Grade 1                 −                  −       −   −      −   −      −   −
  　Grade 2                 −                  −       −   −      −   −      1   6
  Bloating                                                                       
  　Grade 1                 −                  −       1   2      −   −      −   −
  　Grade 2                 −                  −       −   −      −   −      −   −
  Diarrhea                                                                       
  　Grade 1                 2                  6       1   1      −   −      1   5
  　Grade 2                 −                  −       −   −      −   −      1   1
  Constipation                                                                   
  　Grade 1                 1                  2       −   −      1   2      −   −
  　Grade 2                 −                  −       −   −      −   −      −   −
  Bone marrow suppression                                                        
  　Grade 1                 2                  13      −   −      −   −      −   −
  　Grade 2                 −                  −       −   −      1   2      −   −
  Neurotoxicity                                                                  
  　Grade 1                 1                  9       −   −      −   −      1   6
  　Grade 2                 −                  −       −   −      −   −      −   −

Therapeutic evaluation {#s03.04}
----------------------

The therapeutic evaluation of each treatment cycle and follow-up results after treatment are shown in *[Table 5](#Table5){ref-type="table"}*. All the 12 patients were followed up until PD occurred. The median progression-free survival (PFS) was 91 (interquartile range, 88) d. Progression in all the patients was restricted to the originally affected organs, and infiltration into other tissues or organs did not occur.

###### 

Efficiency evaluation and follow-up of enrolled patients

  Number   Efficiency evaluation   PFS (d)        
  -------- ----------------------- --------- ---- -----
  A1       PR                      SD        PD   168
  A2       PD                      −         −    52
  A3       PD                      −         −    36
  B1       SD                      PD        −    105
  B2       PD                      −         −    91
  B3       SD                      SD        PD   138
  C1       PD                      −         −    36
  C2       PD                      −         −    36
  C3       SD                      SD        PD   124
  D1       SD                      SD        PD   90
  D2       SD                      −         −    98
  D3       SD                      SD        PD   135

Six patients obtained SD, and one patient obtained PR after the first treatment cycle. When the MI was 0.4, one patient experienced good treatment efficacy, which was evaluated as PR once (*[Figure 2](#Figure2){ref-type="fig"}*) and SD once, and his PFS was 168 d. When the MI was 0.6, 2 patients (3 times) had SD. When the MI was 0.8, 1 patient (2 times) had SD. When the MI was 1.0, 2 patients (4 times) had SD.

![A patient with hepatic metastases from pancreatic carcinoma was treated with ultrasound combined with microbubbles using a mechanical index (MI) of 0.4 after chemotherapy. (A) Multiple hepatic metastases were measured as baseline data before treatment. The greatest diameter of the largest lesion (red arrow) was 2.6 cm; (B) Lesions decreased in size after the first treatment cycle. The greatest diameter of the largest lesion (red arrow) was 1.8 cm. The patient experienced partial response (PR).](cjcr-30-5-553-2){#Figure2}

Discussion {#s04}
==========

The application of microbubble contrast agents in imaging has been widely clinically accepted ([@b32],[@b33]). Currently, the combination of microbubbles with ultrasound has become a universal theranostic method ([@b34],[@b35]). The sonoporation effect is the mechanical basis for the efficacy of this treatment ([@b36],[@b37]). Sonoporation is defined as the interaction of ultrasound with ultrasonic contrast agents to temporarily permeabilize the cell membrane and allow the uptake of various substances, such as DNA, drugs, and other therapeutic compounds, from the extracellular environment ([@b38]-[@b41]). The role of the sonoporation effect in targeted drug release and gene therapy has been demonstrated in animal experiments ([@b42]-[@b44]). This technique is a promising approach for increasing drug and gene delivery efficiency ([@b38],[@b45]-[@b47]). The primary objective of this study was to explore the safety of ultrasound combined with microbubbles in enhancing the chemotherapeutic sensitivity of malignant tumors in the digestive system. The secondary objective was to preliminarily evaluate the efficacy of this novel method.

This study subjects were patients with advanced malignant tumors of the digestive system. All the chemotherapy regimens were second-line chemotherapies. Other than fever, the other adverse reactions are common complications of second-line chemotherapy. According to the CTCAE V4.03, all the adverse reactions were grade 1 or 2 and resolved after symptomatic treatments. No serious adverse reactions occurred in any of the patients included in the study. In a study by Kotopoulis *et al*. ([@b31]) performed in Norway, treatment with ultrasound combined with microbubbles was shown to enhance the chemotherapeutic efficacy of gemcitabine; 5 patients received treatment 10−27 times and did not experience any increased discomfort with this treatment compared to treatment with chemotherapeutic gemcitabine alone. The study by Dimcevski*et al*. ([@b48]) reported that treatment with ultrasound combined with microbubbles and gemcitabine did not increase patient discomfort compared to treatment with gemcitabine alone. In our study, although fever occurred in 2 patients, they both were grade 1 and resolved with symptomatic treatment. Observing the adverse reactions among the different MIs, the extent and duration of the adverse reactions did not increase with increases in MI. All the patients experienced progression *in situ*, and no new lesions appeared when the patients were followed up until PD occurred. Therefore, when the MI is no greater than 1.0, treatment with ultrasound combined with microbubbles for enhancing chemotherapeutic sensitivity is safe.

Among the 12 patients, one patient with an MI of 0.4 obtained a good curative effect and reached PR after the first treatment cycle. Grade 1 fever (2 times) occurred in this patient, which might be related to the tumor necrosis after treatment. Therefore, an MI of 0.4 can be recommended for evaluation in further studies. An animal experiment by Lin *et al*. ([@b49]) reported that combining ultrasound and microbubbles was able to destruct tumor blood vessels and improve the penetration of liposomal adriamycin into tumor tissue in mice with subcutaneous tumors. The study by Kotopoulis *et al*. ([@b31]) reported that among 5 patients who received the combined treatment with ultrasound, microbubbles and gemcitabine, 2 patients showed significant tumor shrinkage, and 3 patients showed evidence of tumor growth inhibition. In addition, the patients in the study remained in good condition for a longer time than those in the control group. The study by Dimcevski *et al*. ([@b48]) reported that 5 of 10 patients showed a reduction in tumor size after treatment with ultrasound and microbubbles, which enhanced the chemotherapeutic sensitivity of gemcitabine, and the median survival was longer in this group than in the group of patients treated with gemcitabine alone (17.6 months *vs*. 8.9 months, P=0.011). As the chemotherapeutic sensitivities of malignant biliary and ampullary tumors are relatively worse than those of other malignant tumors in the digestive system, the application of ultrasound combined with microbubbles for enhancing the effectiveness of chemotherapy and prolonging patient survival is worth further study and discussion.

The primary limitation of this study was that historical control and random control cannot be formed as the patients' diseases were multiple and the treatment regimens were not uniform. As this study mainly focused on the safety of ultrasound combined with microbubbles, random controlled study to explore effectiveness is needed for further studies.

Despite the many studies on ultrasound-mediated gene and drug delivery using microbubbles, the conditions under which ultrasound-mediated delivery is most effective have not been determined ([@b50]-[@b52]). Although this study identified a relatively good MI, the sample size was small for determining the ideal MI. In addition, there is no consensus on the ideal dosage of microbubbles used to enhance the efficacy of treatment. Further work should be done to determine ideal conditions for better therapeutic effects.

Conclusions {#s05}
===========

Our preliminary data showed that treatment of combining ultrasound and microbubbles for enhancing chemotherapeutic sensitivity of malignant tumors in digestive system was safe when the MI was no greater than 1.0. This study also showed the potential clinical application of the treatment of combining ultrasound and microbubbles.
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